Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy

BACKGROUND: In the USA, more than 50% of patients with ovarian cancer die within 5 years of diagnosis, highlighting the need for therapeutic innovations. Mesothelin (MSLN) is a candidate immunotherapy target; it is overexpressed by ovarian tumors and contributes to malignant/invasive phenotypes, mak...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Kristin G, Oda, Shannon K, Bates, Breanna M, Burnett, Madison G, Rodgers Suarez, Magdalia, Ruskin, Susan L, Greenberg, Philip D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915280/
https://www.ncbi.nlm.nih.gov/pubmed/35264436
http://dx.doi.org/10.1136/jitc-2021-003959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915280/
https://www.ncbi.nlm.nih.gov/pubmed/35264436
http://dx.doi.org/10.1136/jitc-2021-003959

Ejemplares similares